NCT04362501View on ClinicalTrials.gov

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Chronic Sinusitis
Interventions
BIOLOGICAL

dupilumab

300mg dupixent SC every two weeks for six months

DRUG

placebo

placebo SC injection every two weeks for six months

Trial Locations (1)

21224

Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT04362501 - Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Biotech Hunter | Biotech Hunter